SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
DNDN Analysis & Videos »
DNDN: Bull or Bear?
Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: DNDN)
DNDN
|
|
|
-0.62%
in
10 days
 Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space such as Cell Genesys, Favrille, and Genitope; recent advancements and study results are encouraging while Dendreon (NASDAQ: DNDN) awaits a FDA decision that is expected by May 2010 for its prostate cancer vaccine, Provenge, which is poised to become the first active cellular immunotherapy approved by the Agency to harness a patient's own immune system in the fight against the disease. <> Last week, a group of Harvard bioengineers and im...
|
BioMed News Bytes: CombinatoRx, Dendreon, Photocure, Pozen
DNDN
|
|
|
-2.51%
in
8 days
(closed on 11/28/09)
On 11/2/09, Dendreon (NASDAQ: DNDN) announced that it has completed the submission of its amended Biologics License Application (BLA) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer (CRPC). The amended BLA includes data from the IMPACT trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. <> PROVENGE is currently available through several ong...
|
New Global Equity Index to Track Immunotherapy, Vaccine Stocks
DNDN
|
|
|
+5.55%
in
16 days
(closed on 11/20/09)
Earlier this week, Dendreon (NASDAQ: DNDN ) announced that it has completed the submission of its amended Biologics License Application ( BLA ) for PROVENGE (sipuleucel-T), seeking approval for men with metastatic castrate-resistant prostate cancer ( CRPC ). The amended BLA includes data from the IMPACT trial, which was conducted under a Special Protocol Assessment agreement with the FDA. The IMPACT study met its pre-specified primary endpoint demonstrating a statistically significant improvement in overall survival in men with metastatic CRPC. <> PROVENGE is currently ava...
|
New Stock Indexes to Track Trends in Healthcare Sector
DNDN
|
|
|
-0.86%
in
7 days
(closed on 11/04/09)
Coming Soon. . . a premium service offered in collaboration with Investars YOU for full access to a global database of over 1,000 stocks which are organized and managed within my 20 ProActive HavRx stock indexes . The expected pricing for premium access is $60 per year and will include full access to all of the component stocks in the indexes and tracking data for the indexes. <> Emerging Cancer Diagnostic / Therapeutic (Dx / Tx) Index
The actively managed HavRx Emerging Cancer Dx / Tx Index constituents reflect a cross-section of emerging cancer companies with <><><><><><><><><><><><><><><><><><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< /><><><><><><><><><><>< />< /><><>< />< />< />< /><><>< />< /><><>< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< />< />< /><><>< />< /><><><><><><><><><>...
|
Quantum Immunologics: Developing Universal Therapeutic Cancer Vaccine
DNDN
|
|
|
-3.58%
in
3 days
(closed on 10/28/09)
<> <> Quantum Immunologics (QI) (privately held) is dedicated to improving the treatment outcome and quality of life for cancer patients through the research, development, and production of innovative therapeutic and diagnostic products that are based on the universal cancer antigen (oncofetal antigen or OFA). Quantum’s integrated approach to the treatment, diagnosis, and monitoring of cancer is being developed to create novel, individualized products and services that offer a greatly reduced cost, a high rate of efficacy, and minimal side effects compared to conventional treatments such as ra<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
ImmunoCellular (OTC: IMUC.OB): Top Gainer in Cancer Immunotherapy Index
DNDN
|
|
|
+4.25%
in
39 days
(closed on 10/25/09)
<> The Mentor Capital Cancer Immunotherapy (CI) Index of 10 leading cancer immunotherapy stocks has increased 58% in its first two months of reporting. The CI Index gain was paced by the 233% share price improvement of ImmunoCellular Theraputics, Inc. (OTC: IMUC.OB) under the leadership of CEO Manish Singh, PhD. The increased interest in the immunotherapy companies and growth of the sector followed the positive Phase 3 results of Dendreon (NASDAQ: DNDN), a CI Index component company, for its prostate cancer product Provenge and resulting 1,000% share price improvement during the Spring of 200...
|
Quantum Immunologics: Rodman Conference Recap
DNDN
|
|
|
-0.38%
in
23 hours
(closed on 09/16/09)
<> In addition, <> <> <font> QI’s cancer immunotherapy<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Mentor Capital (MNTR.PK) Top Gainer in Cancer Immunotherapy Index
DNDN
|
|
|
+0.30%
in
8 hours
(closed on 08/29/09)
SAN DIEGO--(BUSINESS WIRE)--The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks increased 23% since its inception July 10, 2009. The CI Index was developed by Mentor Capital as a peer group index against which investors could bench mark stock performance in the rapidly growing immunotherapy sector. In this first reporting, the strong six-week CI Index gain was paced by the 78% share price improvement of Mentor Capital, Inc. (Pink Sheets: MNTR - News ). <> <> <> On July 10, 2009, Mentor Capital announced it had acquired a significant interest in an...
|
Mentor Capital (MNTR.PK): A Stealth Cancer Immunotherapy Play
DNDN
|
|
|
-1.70%
in
2 days
(closed on 08/28/09)
<> On 7/8/09 , in the first of four steps leading to an anticipated merger and name change, Mentor Capital (MNTR.PK) acquired a 20% ownership stake in an innovative clinical stage cancer immunotherapy company, <font> Quantum Immunologics, Inc. </font> (QI). QI is a privately held company with a goal of initially marketing its active immunotherapy for the treatment of breast cancer in the U.S. <> , in addition to planning for new studies in other types of cancer and a new cancer screening tool. Mentor Capital is providing funding for QI to complete its ongoing, FDA-authorize...
|
New Indexes to Track Healthcare Trends and More
DNDN
|
|
|
-1.59%
in
22 days
(closed on 08/26/09)
Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis are highlighted below.
Cosmetic & Restorative Medicine Index: Allergan (NYSE:AGN) (+38%) <> The <> ...
|
Access Pharma: A Cancer Biotech Call Option Trade
DNDN
|
|
|
+14.05%
in
69 days
(closed on 08/04/09)
<> The cancer biotech space has attracted the interest of investors, traders, and diversified healthcare giants this year with Johnson & Johnson (NYSE: JNJ) announcing a $1B cash tender offer for Cougar Biotech (NASDAQ: CGRB) last week and Roche's (VTX: ROG) (OTC: RHHBY) mega-deal to acquire full control of Genentech earlier this year. In addition, positive clinical trial results for Dendreon's (NASDAQ: DNDN) Provenge and stock price turnarounds from the brink of zero at Cell Therapeutics (NASDAQ: CTIC) have fueled interest in the small and micro-cap cancer bio-pharma space among investors an...
|
Updated FDA, Clinical Trial Calendars: CTIC, DNDN, MRX, JNJ, MEDX
DNDN
|
|
|
+0.00%
in
1 hour
(closed on 04/14/09)
The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/14/09. The FDA Calendar includes the following information: company name, ticker, decision date, and description. <> <>http://biomedreports.c...
|
BioMed Stock Movers: DNDN, EXAS, KG
DNDN
|
|
|
-225.72%
in
6 days
(closed on 04/14/09)
Dendreon (DNDN) has stalled out around $6.50 per share after a major rally on news of upcoming presentation at a medical conference later this month. DNDN expects to report Provenge clinical trial results some time before the end of April, although it did not guarantee this would occur at the upcoming presentation. The recent spike in shares of DNDN and upcoming presentation do not provide any clarity on whether Provenge results will be sufficient for attaining FDA approval and the pending data release will determine the Company's fate. <> <> <>http://biomedreports.com/article...
|
People Bullish on DNDN
People Bearish on DNDN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on DNDN |
|
|
|
|
tanumoy
(+123.35% risk: conservative)
|
|
|
More Resources
|
About Dendreon Corp
- Answers.com
